Effect of Heated Humidified High Flow Nasal Cannula (HFNC) Oxygen Therapy in Dyspnea Patients with Advanced Cancer, a Randomized Controlled Clinical Trial.
Abstract PurposeHeated humidified high flow nasal cannula(HFNC) oxygen therapy is one of the most important oxygen therapy methods, which are commonly applied to relieve dyspnea in advanced cancer patients. Our study aims to observe the efficacy and safety of HFNC oxygen therapy on dyspnea patients with advanced cancer and explore the clinical application.Methods 60 subjects with advanced cancer requiring oxygen therapy from a Grade 3, Class A hospital in China were recruited and randomized (1:1) to traditional nasal catheter oxygen therapy or HFNC. Primary outcomes were dyspnea, oral dryness and sleep condition, which were recorded after 72-hour treatment. Secondary outcomes were heart rate (HR), respiration rate (RR), SpO2, PaO2 and PaCO2, which were recorded after 2, 6, 24 and 72 hours-treatment.Results72 hours after treatment, there were significant improvement in all primary outcomes (P<0.001). PaO2 and RR were statistically changed 2 hours after HFNC treatment (P<0.001). PaCO2 and HR were statistically changed 24 hours after HFNC treatment (P<0.001). ConclusionHFNC oxygen therapy has good effect, high safety and is easy to be accepted by dyspnea patients with advanced cancer. It can be used as the first choice of oxygen therapy for these patients and has broad clinical prospects.This work was retrospectively registered in the Chinese Clinical Trials Registry (ChiCTR2100049582) on August 4, 2021.
